Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22 CAR-T in Relapsed/Refractory B-ALL
NCT04546906Unknown
- Sponsor
- Senlang Bio
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-CD22 chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Status: unknown.
02
Drugs
anti-CD22 chimeric antigen receptor T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04546906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546906.